The approval of trastuzumab in 1998 has significantly improved patients ... In line with that, our review highlights the well-accepted mechanisms of action and resistance to the therapy and discusses ...

The membrane-associated glycoprotein mucin-4 (MUC4) could block inhibitory actions of trastuzumab by directly binding with HER2, preventing interaction between the drug and its molecular target.

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Identifying and validating this biomarker helped develop drugs like Herceptin ... and physiological effects of drugs and their mechanisms of action. PD measurements generate biomarker data ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

This article will review the mechanisms of activation of alternative, classical, and lectin pathways, the formation of C3 and C5 convertases, the action of anaphylatoxins, and the ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...